A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...
BeOne Medicines Ltd. ONC shares are trading lower on Tuesday as the company shared topline results from its Phase 3 MANGROVE ...
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a ...
Company AnnouncementTopline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated ...
Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL.
Increasing frontline covalent BTK inhibitor use and emerging BTKi+BCL2i+anti-CD20 triplets constrain the R/R BTK-naïve ...
In this video, Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and a staff physician at the Cleveland Clinic Cancer Institute, discusses new and upcoming treatments for mantle ...
AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial. The companies said Monday the combination of epcoritamab and lenalidomide demonstrated ...
Skin rashes can be a real nuisance, but they're generally benign. However, there is one time when that incessant itching can ...
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...
In this video, Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and a staff physician at the Cleveland Clinic Cancer Institute, discusses his approach for treating patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results